PRKN and cancer: Disorders resulting from mutations in the PARK2 gene are detected in approximately 30% of cancers, including lung, liver, intestine, and brain cancers; mice lacking the gene encoding parkin are more susceptible to developing cancer [110,111,112,113,114].